CollPlant Biotechnologies (CLGN) Inventory Average (2018 - 2024)
CollPlant Biotechnologies' (CLGN) quarterly Inventory Average came in at $447.0 million in Q4 2024, down 40.55% YoY from $751.9 million in Q1 2024, and up 96.73% on a QoQ basis from $227.2 million in Q3 2024.
CollPlant Biotechnologies (CLGN) Inventory Average (2018 - 2024) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 7 years of Inventory Average data on file, last reported at $447.0 million in Q4 2024.
- Quarterly Inventory Average fell 40.55% year-over-year to $447.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $447.0 million (down 40.55% YoY) and the FY2025 annual result came in at $220.3 million, changed 0.03% from the prior year.
- Inventory Average climbed to $447.0 million in Q4 2024, from $227.2 million in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $540.5 billion in Q1 2022 to a low of $848500.0 in Q3 2020.
- A 5-year average of $54.3 billion and a median of $383.7 million in 2020 frame the typical range for Inventory Average.
- Annual changes were most pronounced in 2021 — Inventory Average jumped 48497035.62% — and 2022, when it plunged 99.87%.
- Tracing CLGN's Inventory Average over 5 years: stood at $1.1 million in 2020, then jumped by 48497035.62% to $540.5 billion in 2021, then sank by 99.87% to $715.6 million in 2022, then climbed by 5.07% to $751.9 million in 2023, then plunged by 40.55% to $447.0 million in 2024.
- The last three Inventory Average figures came in at $447.0 million (Q4 2024), $227.2 million (Q3 2024), and $322.7 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 213.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 707.10 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 90.57 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 137.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 196.36 Mn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 447.00 Mn |
| Sep 30, 2024 | 227.22 Mn |
| Jun 30, 2024 | 322.72 Mn |
| Mar 31, 2024 | 322.86 Mn |
| Dec 31, 2023 | 751.86 Mn |
| Sep 30, 2023 | 752.28 Mn |
| Jun 30, 2023 | 1.67 Mn |
| Mar 31, 2023 | 715.89 Mn |
| Dec 31, 2022 | 715.56 Mn |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 1.31 Mn |
| Mar 31, 2022 | 540.50 Bn |
| Dec 31, 2021 | 540.50 Bn |
| Sep 30, 2021 | 1.05 Mn |
| Jun 30, 2021 | 637.97 Mn |
| Mar 31, 2021 | 638.13 Mn |
| Dec 31, 2020 | 1.11 Mn |
| Sep 30, 2020 | 848,500.00 |
| Jun 30, 2020 | 918,500.00 |
| Mar 31, 2020 | 444.55 Mn |